Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PT Soho Global Health Tbk's earnings before interest and taxes (EBIT) for the
three
months ended in Jun. 2026 was Rp234,810 Mil.
Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Jun. 2026 was Rp879,101 Mil.
EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.
PT Soho Global Health Tbk's annualizedROC % for the quarter that ended in Jun. 2026 was 31.80%.
PT Soho Global Health Tbk's annualizedROC (Joel Greenblatt) % for the quarter that ended in Jun. 2026 was 61.92%.
EBIT is also linked to Joel Greenblatt's definition of earnings yield.
PT Soho Global Health Tbk's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2026 was 6.03%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Distribution subindustry, PT Soho Global Health Tbk's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PT Soho Global Health Tbk EV-to-EBIT vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, PT Soho Global Health Tbk's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where PT Soho Global Health Tbk's EV-to-EBIT falls into.
EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.
EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was Rp879,101 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PT Soho Global Health Tbk (ISX:SOHO) has a EBIT of Rp879,101 Mil as of Jun. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on PT Soho Global Health Tbk.
Is PT Soho Global Health Tbk's EBIT too high?
PT Soho Global Health Tbk's current EBIT is Rp879,101 Mil. Overall, PT Soho Global Health Tbk has a GF Score™ of 85/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does PT Soho Global Health Tbk's EBIT compare to MCK and COR?
PT Soho Global Health Tbk's EBIT of Rp879,101 Mil can be compared against companies in the Medical Distribution industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Medical Distribution company?
A good EBIT depends on the Medical Distribution industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on PT Soho Global Health Tbk. PT Soho Global Health Tbk's current EBIT is Rp879,101 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PT Soho Global Health Tbk stock overvalued right now?
Based on GuruFocus' analysis, PT Soho Global Health Tbk (ISX:SOHO) is currently considered Significantly Overvalued. The stock's GF Value™ is Rp805.04, compared to a current price of Rp1,205.00 — trading 49.7% above its estimated fair value. The current EBIT is Rp879,101 Mil. PT Soho Global Health Tbk's overall GF Score™ is 85/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For PT Soho Global Health Tbk (ISX:SOHO), the current EBIT is Rp879,101 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PT Soho Global Health Tbk (ISX:SOHO) Overvalued in 2026?
Based on GuruFocus' analysis, PT Soho Global Health Tbk stock appears to be overvalued.
The current stock price of Rp1,205.00 is trading 49.7% above its estimated GF Value™ of Rp805.04.
GuruFocus considers PT Soho Global Health Tbk to be Significantly Overvalued.
Key valuation signals for ISX:SOHO:
EBIT: Rp879,101 Mil
GF Value™: Rp805.04 vs. price of Rp1,205.00 (49.7% above fair value)
No single metric tells the full story. See the ISX:SOHO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PT Soho Global Health Tbk is a healthcare company operating in the areas of natural/herbal health care products and services. The company manufactures and distributes pharmaceutical products, including herbal cures, proprietary medicines, and health foods, under various brand names such as Curcuma Plus, Curcuma Plus Milk; Imboost; Fitkom; Diapet; Laxing; Lelap; Asthma Soho, and Sohobion. Its segment includes Distribution, Consumer health, Alliance, and others. The company generates maximum revenue from the Distribution segment.
85GF Score
Get the complete analysis for ISX:SOHO
EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ISX:SOHO has been successfully added to your 
